ADJUVANT TRASTUZUMAB THERAPY IN HER2-POSITIVE BREAST CANCER PATIENTS: A META-ANALYSIS OF PUBLISHED RANDOMIZED TRIALS

被引：0
|
作者：
Xia, Y. [1 ]
Bian, B. [1 ]
Costea, E. [2 ]
Kelton, C. M. [3 ]
Guo, J. J. [4 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] Cincinnati VAMC, Cincinnati, OH USA
[3] Univ Cincinnati, Coll Business, Cincinnati, OH USA
[4] Univ Cincinnati, Coll Pharm, Cincinnati, OH 45267 USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.622
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [1] Adjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer Patients: A Meta-Analysis of Published Randomized Trials
    Xia, Ying
    Bian, Boyang
    Costea, Elizabeth
    Guo, Jeff
    Kelton, Christina
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 131 - 132
  • [2] Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
    Yin, Wenjin
    Jiang, Yiwei
    Shen, Zhenzhou
    Shao, Zhimin
    Lu, Jinsong
    [J]. PLOS ONE, 2011, 6 (06):
  • [3] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Gustavo A Viani
    Sergio L Afonso
    Eduardo J Stefano
    Ligia I De Fendi
    Francisco V Soares
    [J]. BMC Cancer, 7
  • [4] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Viani, Gustavo A.
    Afonso, Sergio L.
    Stefano, Eduardo J.
    De Fendi, Ligia I.
    Soares, Francisco V.
    [J]. BMC CANCER, 2007, 7 (1)
  • [5] Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤2cm: A meta-analysis of the randomized trastuzumab trials.
    O'Sullivan, Ciara Catherine Maria
    Bradbury, Ian
    De Azambuja, Evandro
    Perez, Edith A.
    Rastogi, Priya
    Spielmann, Marc
    Joensuu, Heikki
    Ballman, Karla V.
    Costantino, Joseph P.
    Delaloge, Suzette
    Zardavas, Dimitrios
    Piccart-Gebhart, Martine J.
    Zujewski, JoAnne
    Holmes, Eileen McCormick
    Gelber, Richard D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [7] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Angelica Fasolo
    Elena De Benedictis
    Luca Gianni
    [J]. Nature Clinical Practice Oncology, 2009, 6 : 93 - 104
  • [8] Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
    Guarneri, V
    Griguolo, G.
    Miglietta, F.
    Conte, P. F.
    Dieci, M., V
    Girardi, F.
    [J]. ESMO OPEN, 2022, 7 (02)
  • [9] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [10] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
12345